Alkahest to Present Positive Data from Completed Phase 2 Clinical Trial at the 15th International Conference on Alzheimer’s and Parkinson’s Disease

March 8, 2021, SAN CARLOS, Calif . – Alkahest, Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases and a subsidiary of Grifols, today announced it will be delivering a presentation of data from a completed study of its therapeutic plasma fraction candidate, GRF6021, in subjects with Parkinson’s disease (PD) and cognitive impairment at the virtual 15 th International Conference on Alzheimer’s and Parkinson’s Diseases. Presentation and discussion session details are included below. Presentation Details: Title: A Randomized, Double-blind, Placebo-controlled Trial Assessing The Safety And Tolerability Of GRF6021 In Subjects With Parkinson’s Disease And Cognitive Impairment Presenter: Esther Rawner, M.D., Senior Medical Director Date: Wednesday, March 10, 2021 Time: 14:00 – 14:15 CET Session: Translational Treatment Strategies 1 Conference Registration and Access Link: https://adpd.kenes.com/register/ Discussion Session Details: Date: Wednesday, March 10, 2021 Time: 17:00 – 17:30 CET Alkahest is studying GRF6021 as a potential treatment for age-related diseases in collaboration with clinical development partner and parent company, Grifols. GRF6021 is a proprietary plasma fraction that has enhanced neurogenesis, improved age-related deficits in learning and memory and reduced neuroinflammation in preclinical animal models. In its phase 2 clinical study of GRF6021 in subjects with PD and cognitive impairment, GRF6021 demonstrated positive effects on cognitive endpoints in PD patients with cognitive impairment and was safe and well tolerated by study participants. Alkahest plans to further study efficacy of GRF6021 in patients to advance its clinical development.

The release as fetched from its publisher. grifols.com ↗